Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology.

Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.

Key Stats

• Today's Range: $2.85 to $2.95
• 50-Day Range: $2.19 to $2.93
• 52-Week Range: $1.54 to $3.07
• Volume: 354,516 shs
• Average Volume: 368,548 shs
• Market Capitalization: $265.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Stereotaxis Stock Analysis - MarketRank™

Stereotaxis scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Stereotaxis.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stereotaxis are expected to grow in the coming year, from ($0.26) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stereotaxis is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stereotaxis is -10.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stereotaxis has a P/B Ratio of 41.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.99% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Stereotaxis has recently decreased by 13.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stereotaxis does not currently pay a dividend.

Dividend Growth

Stereotaxis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.99% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Stereotaxis has recently decreased by 13.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.17

News Sentiment

Stereotaxis has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Stereotaxis this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stereotaxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.77% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STXS Stock Analysis - Frequently Asked Questions

How have STXS shares performed this year?

Stereotaxis' stock was trading at $2.29 on January 1st, 2025. Since then, STXS stock has increased by 27.5% and is now trading at $2.92.

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its quarterly earnings results on Monday, November, 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The business earned $9.20 million during the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative trailing twelve-month return on equity of 440.00% and a negative net margin of 73.43%.
Read the conference call transcript.

Who are Stereotaxis' major shareholders?

Top institutional investors of Stereotaxis include Geode Capital Management LLC (1.72%), Warberg Asset Management LLC (1.40%), Prescott Group Capital Management L.L.C. (1.32%) and State of Wyoming (0.43%).
View institutional ownership trends.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stereotaxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 9/25/2025
• Next Earnings (Estimated): 11/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.05 million
• Net Margins: -73.43%
• Pretax Margin: -73.43%
• Return on Equity: -440.00%
• Return on Assets: -50.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.06
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $26.92 million
• Price / Sales: 9.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 41.57

Miscellaneous

• Outstanding Shares: 91,070,000
• Free Float: 74,888,000
• Market Cap: $265.01 million
• Optionable: Not Optionable
• Beta: 1.61